Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2024-12-08
Based on 1230 first isolates · PHC-N · Cystitis (lower UTI) · 2023-12-10 → 2024-12-08
Health centre North
Per-organism detail: PHC-N urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 84 % (81 %–86 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (8 %), Pseudomonas aeruginosa (5 %), Klebsiella pneumoniae (3 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
84 %
92 %
n = 97
meropenem MEM
trend · Escherichia coli reserve
82 %
85 %
n = 97
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
79 %
84 %
n = 97
ceftriaxone CRO
trend · Escherichia coli
75 %
81 %
n = 97
mecillinam MEC
trend · Escherichia coli lower UTI only
75 %
81 %
n = 97
ciprofloxacin CIP
trend · Escherichia coli
75 %
80 %
n = 97
72 %
76 %
n = 97
trimethoprim TMP
trend · Escherichia coli lower UTI only
72 %
73 %
n = 97
51 %
61 %
n = 97
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
15 %
12 %
n = 97
5 %
2 %
n = 97
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
2 %
n = 97

Most likely organisms for this profile

Escherichia coli
50 %
Klebsiella pneumoniae
13 %
Enterococcus faecalis
11 %
Proteus mirabilis
8 %
Pseudomonas aeruginosa
5 %
Staphylococcus aureus
3 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.